Summary
57 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 82 USD is left as net profit.
- Revenue grew by 184% a year over the last 3 years.
- It holds more cash than debt: $133.8M against $13.1M.
- The share price is below the Bulios Fair Price.
What to watch
- Operating profit covers the interest on its debt only 1.8 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 26% a year over 5 years. Over the last 3 years it grew by 184% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales -32 USD
- Research and development 39 USD
- Sales and administration 61 USD
- Taxes and other -48 USD
- Net profit 82 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 82 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 3.0 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $79.17 is 74% above today's price. 74% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.